Related Experiment Video
Updated: Mar 2, 2026

A Gut-on-a-Chip Model to Study the Gut Microbiome-Nervous System Axis
Published on: July 28, 2023
The entero-insular axis: implications for human metabolism
1Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK. lrang@liv.ac.uk
Incretins, like GLP-1 and GIP, offer a new approach to treating type 2 diabetes by improving glucose control and beta-cell function. These hormones may also help manage obesity and neurodegenerative diseases.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Incretins (GIP and GLP-1) are key hormones regulating glucose homeostasis after nutrient intake.
- Current type 2 diabetes (T2D) treatments are often inadequate, failing to address beta-cell failure and causing weight gain.
- Obesity is a major driver of the T2D epidemic, necessitating novel therapeutic strategies.
Purpose of the Study:
- To explore the therapeutic potential of incretin-based agents for type 2 diabetes (T2D).
- To investigate incretin's role in managing obesity and potential neurodegenerative disorders.
- To highlight the limitations of existing T2D treatments and the need for improved glycemic control.
Main Methods:
- Review of existing literature on incretin physiology and T2D pathogenesis.
- Analysis of clinical trial data for incretin analogues and DPPIV inhibitors.
- Exploration of incretin receptor presence and function in the brain.
Main Results:
- Incretin metabolism is impaired in T2D, with reduced secretion and GIP resistance.
- GLP-1 administration improves insulin secretion and glucose homeostasis in T2D.
- Developed incretin analogues and DPPIV inhibitors show effectiveness in clinical trials, with ongoing research for oral agents.
Conclusions:
- Incretin-based therapies represent a promising new avenue for T2D treatment, potentially improving glycemic control, minimizing weight gain, and preserving beta-cell function.
- Further research and ongoing clinical trials are needed to determine optimal incretin-based strategies and their full therapeutic potential in T2D and other conditions like obesity and neurodegeneration.
More Related Videos
Related Concept Videos
Overview of Metabolism
Plant Metabolism
Sunlight, the primary source of energy in plants, is first absorbed by the chlorophyll pigments present in their leaves. Plants then use this energy to carry out photosynthesis, where water is oxidized into oxygen and carbon dioxide...
Regulation of Metabolism
Physiology of the Gastrointestinal System II: Digestion and Absorption
Digestion begins in the mouth, where food undergoes mechanical breakdown by chewing and combines with saliva. Salivary amylase, an enzyme in saliva, starts the breakdown of starches into maltose. The food then travels down the esophagus to the stomach.
In the stomach, a...
Metabolic States of the Body: The Absorptive State
Metabolic States of the Body: The Postabsorptive State
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...

